Wednesday, July 8, 2026

Patent intelligence · US

US 11571431

Aramchol salts

granted A61KA61K31/575A61K9/0053A61K9/4816
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 17
Applicant portfolio 11
Patent details — US 11571431
Jurisdiction
US
Status
granted
Grant date
Feb 7, 2023
Expiration
Feb 2, 2043
Claims
13
CPC classes
A61K, A61K31/575, A61K9/0053, A61K9/4816
View on Google Patents ↗

Quick answer

US 11571431 (Aramchol salts) is held by GALMED RESEARCH AND DEVELOPMENT LTD. Status: granted. Granted Feb 7, 2023. Expires Feb 2, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
13
CPC classes
A61K, A61K31/575, A61K9/0053, A61K9/4816

More from GALMED RESEARCH AND DEVELOPMENT LTD

Related pharmaceutical patents in our USPTO index.

  1. US 12239712

    Combination therapy for the treatment of liver disease

    GALMED RESEARCH AND DEVELOPMENT LTD · Expires Feb 27, 2045

    granted
  2. US 11197870

    Treatment for hepatic fibrosis

    GALMED RESEARCH AND DEVELOPMENT LTD · Expires Dec 9, 2041

    granted
  3. US 11166964

    Treatment for modulating gut microbiota

    GALMED RESEARCH AND DEVELOPMENT LTD · Expires Nov 4, 2041

    granted
  4. US 10849911

    Low dose compositions of Aramachol salts

    GALMED RESEARCH AND DEVELOPMENT LTD · Expires Nov 26, 2040

    granted
  5. US 8975246

    Bile acid or bile salt fatty acid conjugates

    GALMED RESEARCH AND DEVELOPMENT LTD · Expires Mar 5, 2035

    granted
  6. US 8110564

    Bile acid or bile salt fatty acid conjugates

    Galmed International Limited · Expires Feb 2, 2032

    granted
  7. US 7501403

    Bile acid or bile salt fatty acid conjugates

    Galmed International Limited · Expires Mar 5, 2029

    granted

Frequently asked questions

What is US patent 11571431?

US 11571431 (Aramchol salts) is held by GALMED RESEARCH AND DEVELOPMENT LTD. Status: granted. Granted Feb 7, 2023. Expires Feb 2, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11571431?

GALMED RESEARCH AND DEVELOPMENT LTD is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 11 pharmaceutical patents for this assignee.

When does US 11571431 expire?

Our index shows an expiration date of Feb 2, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.